Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LB1410 + lenvatinib + LB4330
- Development stage
- Phase 3
- Lead developer
- L&L Biopharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
LB1410 + lenvatinib + LB4330 is a multi-pronged combination therapy developed by L&L Biopharma to treat advanced cancers that have become resistant to anti-PD-1/PD-L1 therapies. The regimen consists of **LB1410**, a recombinant humanized bispecific antibody that simultaneously blocks the Programmed Cell Death Protein 1 (PD-1) and T-cell Immunoglobulin and Mucin-domain containing-3 (TIM-3) pathways; **lenvatinib**, a small-molecule tyrosine kinase inhibitor (TKI) targeting Vascular Endothelial Growth Factor Receptors (VEGFR 1-3) to inhibit angiogenesis; and **LB4330**, a long-acting Interleukin-10 (IL-10) cytokine fusion protein designed to modulate the tumor microenvironment. This combination is being evaluated in Phase 2/3 trials for anti-PD-1 resistant cervical cancer and renal cell carcinoma, aiming to overcome immune evasion and reactivate anti-tumor immunity through dual checkpoint blockade, anti-angiogenesis, and cytokine-mediated immunomodulation.
- Other names
- LB1410 + TKI + LB4330
02
Targets
Claudin 18.2IL10RA (Interleukin-10 Receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)VEGFR (VEGFR family)
Beyond the preview
Go deeper on LB1410 + lenvatinib + LB4330.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LB1410 + lenvatinib + LB4330.